



RxFiles – Drug Comparison Charts 10th Edition (Oct 2014)



CHART PEARLS 10th Edition

Highlights of Just a Few of the Revisions

Guidelines Reviewed & Incorporated into Charts

AAP '13 Drugs into Human Breast Milk/Lactation, ACOG HRT & Heart Dx, ADA '14 Diabetes, AHA '13 Obesity & Lipid Guidelines, ASH/ISH BP Guide, CCS '12 Heart Failure & Dyslipidemia, CDA '13 Diabetes Guideline, CHEP '14, CPSC '12 Parkinson's, JNC8 **etc**

WARFARIN TIPS & NOMOGRAM

Pg 11-12

- Tips for initiating warfarin, managing drug interactions, dosing and monitoring INRs

ANTICOAGULANT COLOR COMPARISON OF AGENTS

Pg 21-22

- New chart comparing warfarin to the new oral anticoagulants regarding bleeding, common side effects & outcomes

OPIOID TAPERING GUIDE

Pg 102

- Management of common withdrawal side effects and an appropriate timeline for a gradual taper

MIGRAINE OVERVIEW & MANAGEMENT

Pg 117-118

- Strategies for both preventive and acute migraine therapies
- How to spot RED FLAG signs and symptoms in acute migraines

Approach to Tapering in Older Adults– Considerations

Pg 157-158

- Overview of strategies for tapering medications

New Charts - 12 in all

- Warfarin Tips & Nomogram Pg 11-12
- Antiplatelets & Antithrombotics: Perioperative Management Pg 13-14
- Anticoagulant Color Comparison of agents Pg 21-22
- Diabetes Color Comparison of agents Pg 35
- Colonoscopy Bowel Preparations Pg 54-55
- Management of Constipation Pg 56-59
- Pain Overview of Approach & Tx Pg 93-94
- Opioid Tapering Guide Pg 102
- Perioperative Pain Management Pg 103
- Migraine Overview & Approach Pg 117-118
- Abnormal Uterine Bleeding Pg 123-124
- An Approach to Tapering in Older Adults Pg 157-158

New Drug (Brand Name) Additions

AUBAGIO, ANORO & BREO ELLIPTA, AXIRON, BELVIO, BEXSERO, BYSTOLIC, DIFICID, DIVIGEL, EMTRIX, ESTROGEL PROPAG, FYCOMPA, GALEXOS, INTUNIV (XR), JUBLIA, LATUDA, LINZESS, MYBETRIQ, NEUPRO, OLUX-E, POTIGA, RESOTRAN, SEEBRI & ULTIBRO BREEZHALER, SILENOR, SOVALDI, STENDRA, STRIBILD, TECFIDERA, TOVIAZ, TUDORZA, TYBOST, VITEKTA, XELJANZ, ZAXINE, ZIOPTAN

Scanning Through The Charts

- Hypertension - updated BP target for ≥80yrs ^{Systolic <150mmHg} pg 2
- Diabetes – new class of antihyperglycemics (SGLT2 inhibitors) on the market; lack outcome data pg 38
- Hepatitis C – new drugs: GALEXOS and SOVALDI pg 84
- Antibiotics - Fosfomycin for acute cystitis pg 91
- Analgesic Ladder adapted for the new WHO & Canadian Opioid Guide pg 93
- Phantom limb pain evidence summary pg 95

By the Numbers

Total pages: 188. New pages: 20. New charts: 12.

Changes: **thousands**. Charts updated **daily**, then to web/apps.

Pregnancy & Lactation Symbols

See page 2 for the RxFiles risk categories.

\$ Comparisons^{/30day} that caught our



Generics soon to be unavailable for a while:

Nortriptyline, Valacyclovir

Oral Contraceptives pg 126:

ALESSE g = ALYSENA/ESME/LUTERA

\$190/yr

New TRI-CYCLEN LO g = TRICIRA LO

\$185/yr

New YASMIN g = ZAMINE/ZARAH

\$179/yr

New YAZ g = MYA

\$216/yr

SELECT

\$161/yr

Substantially **REDUCED** SK Formulary Cost

Latanoprost/Timolol g = XALACOM oph. susp.

\$23

Zoledronic Acid g = ACLASTA 5mg IV

\$563[⊗]

Almotriptan g = AXERT 6.25mg or 12.5mg

\$56^{/6doses}[⊗]

Mometasone furoate lotion g = ELOCOM 60g

\$31

Mometasone nasal spray g = NASONEX 1 bottle

\$34

Alendronate g = FOSAVANCE 70mg/5600IU weekly

\$280[⊕]

Risedronate g = ACTONEL 150mg monthly

\$376[⊕]

Risperidone ODT g = RISPERDAL M-TAB 1mg bid

\$44

Status & Reimbursement Changes

- **On SK Formulary:** ASMANEX TWISTHALER, CYMBALTA, EPURIS, Fluconazole, JURNISTA, LOSEC 20mg, LYRICA, PARIET, TACTUPUMP
- **New EDS** [⊕]: ACLASTA, ACTONEL DR, BANZEL, BIPHENTIN, CIMZIA, COMPLERA, Dabigatran, DIVIGEL, ELIQUIS, EZETROL, JANUVIA 25mg & 50mg, JENTADUETO, Nabilone, ONBREZ, Rilpivirine, SAPHRIS, Saxagliptin 2.5mg, SEEBRI BREEZHALER, STRIBILD, TOVIAZ, VYVANSE, XARELTO, ZENHALE, ZOFRAN ODT
- **New generics**[⊕]: ACCUPRIL, ACTONEL 150mg, ARTHROTEC, Atomoxetine, AXERT, Bupropion XL, Ciprofloxacin, Donepezil, ELOCOM lotion, Entecavir, FOSAVANCE, LESCOL, NASONEX, RELPAX, RISPERDAL M-TAB, SUSTIVA, Theophylline, XALACOM, YASMIN
- **New full NIHB** [⊕]: ASMANEX TWISTHALER, CIPRALEX, CONCERTA, EVRA, LEVEMIR, MAGIC BULLET, NUVARING, ONDISOLVE, TWYNSTA, WELLBUTRIN XL, YAZ
- **New prior NIHB approval** [⊕]: ATRIPLA, BANZEL, CIMZIA, Dabigatran, INTELLIGENCE, JANUVIA, JANUMET, LYRICA, Nabilone, ONBREZ BREEZHALER, Rivaroxaban, Saxagliptin, TRAJENTA, VIMPAT, Injectable opiates
- **Removed from NIHB** [⊗]: DEMEROL, Ketorolac, OXYNEO, RITALIN (Brand only), TYLENOL #4

Outcome Evidence from MAJOR Trials

Major outcome trials & drug dosages used are often noted on charts when pertinent. Relatively recent: **Aspire** (Low-dose Aspirin for recurrent VTE page 16), **CitAD** (citalopram for Alzheimer's Dx page 110), **CNT** ^{collaboration} (CV & GI AE: Coxib vs NSAID page 98), **Freedom** (PCI vs CABG), **GuidAge** (Gingko vs placebo page 128), **HPS2-Thrive** (Niacin + Laropiprant vs placebo page 26), **SAVOR-TIMI 53** (Saxagliptin vs placebo page 35), **SPS3** (Aspirin+Clopidogrel vs Aspirin page 8), **Woest** (Clopidogrel & warfarin +/- ASA in PCI page 15)

RxFiles Academic Detailing c/o Saskatoon City Hospital, 701 Queen Street, Saskatoon, SK Canada S7K 0M7
TEL: (306) 655-8505 FAX: (306) 655-7980 Email: via our website. www.RxFiles.ca

See our website for subscription options on accessing our information online. Saskatchewan health professionals have free automatic access through health regions/universities, or individually through SHIRP.

Recent Adverse Reaction Advisories

Health Canada [Advisories, Warnings and Recalls - Health Canada](#) & FDA

- ARZERRA (ofatumumab)**: Recommendations to screen, monitor and manage Hepatitis B virus reactivation
- EFFIENT (prasugrel hydrochloride)**: Increased risk of bleeding in patients treated in hospital for certain types of heart attacks
- Levonorgestrel containing ECPs**: Evaluation of the effectiveness in women over a certain weight
- Lithium**: Risk of hypercalcemia and hyperparathyroidism
- Ketoconazole**: Warnings of adrenal and liver complications
- REMERON, SEROQUEL, CELEXA, ZOFRAN**: ↑QT syndrome reports
- REVLIMID (lenalidomide)**: Risk of liver problems
- SUBLINOX (zolpidem tartrate)**: Decreased dosage recommendations for elderly as well as female patients
- XELODA (capecitabine)**: Risk of severe skin reactions

Pictures & Colors Speak 1000 Words

COLOURS USED WITHIN THE CHARTS

Green shading usually indicates HERBAL/LIFESTYLE related
Blue shading usually indicates PEDIATRIC related
Dark Blue shading usually indicates ADOLESCENT related
Tan shading usually indicates ELDERLY related
Purple script usually indicates TRADE NAMES
Yellow highlights CLINICAL DIFFERENCES, PRACTICE GAPS & COMMON ?'s
Blue script usually indicates MAJOR TRIALS
Pink script usually indicates PREGNANCY & LACTATION related
Red shading usually indicates official FDA black box or HC warning
Gray script usually indicates DISCONTINUED drug
Purple shading usually indicates OVERVIEW/GUIDELINE approach

☺ Your notes...

RxFiles Online www.RxFiles.ca

- Newsletters, Q&As, Trial Summaries available to all.
- Updated charts available to those with subscription.
- Links / Program Information / References / Search Feature / Online Store / iPad, iPhone, Android.
- RxFiles *Email Notification* of new postings.

All Charts sizes (pocket, standard & oversized) are tabbed.

Link to order form: <http://www.rxfiles.ca/rxfiles/uploads/documents/1A-CHT-Book-ORDERFORM.pdf>

Editors: Brent Jensen, Loren Regier

SYMBOLS

	Canada (We are Canadian)
	Non-formulary in Saskatchewan
	Exception Drug Status (EDS) in Saskatchewan (SK) (1-800-667-2549)
	Not covered by NIHB (Non-Insured Health Benefits) http://www.hc-sc.gc.ca/fnihb/nihb/pharmacy/drugbenefitlist/index.htm
	Prior approval required by NIHB. Coverage for eligible First Nations & Inuit (1-800-580-0950)
	Covered by NIHB. Found on the OTC charts (pgs 135-138) & identified ONLY for those drugs which have SK Formulary restrictions such as EDS or non-formulary status .
	Retail <i>Cost to Consumer</i> based on acquisition cost, markup & dispensing fee in Saskatchewan. Lowest generic price used where available.
	Free Medication coverage provided by the Saskatchewan Cancer Centre
	Herbals: likely safe
	Herbals: possibly safe
	Tablet is scored. Appears as superscript, e.g. 25 ^c mg tablet.
	Tastes good
	Concern if drug or herbal is given Pre-Op
	Avoid if patient has soybean & peanut allergy
	Male
	Female
	Dose ↓ may be required for liver dysfunction
	Dose ↓ required for renal dysfunction <i>if</i> 1) drug ≥ 75% renal excretion 2) toxic if accumulates 3) an active metabolite requiring dose adjustment. [CrCl <60ml/min indicates impaired renal function]

COMMONLY USED ABBREVIATIONS

AE	Adverse event
BID	Twice daily
BP	Blood pressure
Bz	Benzodiazepine
CI	Contraindication
CV	Cardiovascular
DI	Drug interaction
Dx	Diagnosis/disease
HSR	Hypersensitivity reaction
LFT	Liver function tests
M	Monitoring
OTC	Over the counter
p	Porphyria
QID	Four times daily
eGFR	Estimated glomerular filtration rate
g	Generic available
GI	Gastrointestinal
HA	Headache
HF	Heart failure
HR	Heart rate
HS	Bedtime
SCr	Serum creatinine
SJS	Stevens Johnson Syndrome
Sx	Syndrome/symptom
Sz	Seizure
TID	Three times daily
Tx	Treatment/Therapy



DRUGS IN PREGNANCY & LACTATION RISK CATEGORIES

PREGNANCY [P]	LACTATION [L]
Safe [P]	Safe [L]
• Compatible in pregnancy	• Compatible in breastfeeding
Likely Safe [P]	Likely Safe [L]
• No (limited) human data – probably compatible • Compatible: maternal benefit >> embryo-fetal risk • Human data suggest low risk	• No (limited) human data – probably compatible
Caution [P]	Caution [L]
• Human, and or animal, data suggest risk [P] • Potential risk in specific trimester(s), as indicated by 'x' [P _x]	• Hold/delay breastfeeding • No (limited) human data – potential toxicity
Contraindicated [P]	Contraindicated [L]
• Contraindicated in pregnancy [P] • Contraindicated in specific trimester(s), as indicated by 'x' [P _x]	• Contraindicated in breastfeeding
Unknown for Pregnancy [P] and/or Lactation [L]	What you'll see in the charts: P = pregnancy L = lactation risk category Colours correspond to risk categories outlined in this table. Example, warfarin: P = contraindicated 1 st trimester L = compatible during lactation
• No (limited) human data – no relevant animal data	
Reference: Drugs in Pregnancy and Lactation. 9th ed. Briggs GE, Freeman RK, Yaffe SJ, editors. Williams and Wilkins; Philadelphia, PA: 2011.	